Treatment of neovascular age-related macular degeneration: Current therapies

Clinical Ophthalmology

Volumn 3, Issue 1, 2009, Pages 175-182

  Augustin, Albert J ^a   Scholl, Stefan ^a   Kirchhof, Janna ^a  

^a Klinikum Karlsruhe   (Germany)

Author keywords

Anti angiogenesis; Neovascularization; PDT; Steroids; Wet AMD

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

ABSENCE OF SIDE EFFECTS; ARGON LASER; BLEEDING; CLINICAL TRIAL; DEATH; DISEASE COURSE; DRUG COST; DRUG MECHANISM; EYE INFLAMMATION; FLUORESCENCE ANGIOGRAPHY; HEART INFARCTION; HUMAN; INJECTION SITE INFLAMMATION; INTRAOCULAR HYPERTENSION; LASER COAGULATION; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIDE EFFECT; STROKE; SUBRETINAL NEOVASCULARIZATION; THROMBOSIS; VISUAL ACUITY;

EID: 77953420995     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s3926     Document Type: Review

References (48)

1. Haab O. Erkrankungen der macula Lutea. Zentralbl Augenheilkd. 1885;9:384-391.
2. Nettleship E. Central areolar choroidal atrophy. Trans Ophthalmol Soc U K. 1884;4:165-166.
3. Leibowitz HM, Krueger DA, Maunder RA, et al. The Framingham Eye Study monograph; an ophthalmological study of cataract, glaucoma, diabetic retinopathy, macular degeneration and visual acuity in a general population of 2631 adults 1973-75. Surv Ophthalmol. 1980;24(Suppl):335-610.
4. Friedman DS, O'Colmain BJ, Muñoz B, et al; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572.
5. Congdon N, O'Colmain B, Klaver CC; the Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-485.
6. Augood CA, Vingerling JR, de Jong PTVM, et al. Prevalence of agerelated maculopathy in older Europeans. The European Eye Study (EurEye). Arch Ophthalmol. 2006;124:529-535.
7. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367-374.
8. Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1976;81: 383-396.
9. Coscas G, Soubrane G. Photocoagulation des neo vaisseaux sous-retiniens dans la degenerescence maculaire senile par laser a argon; resultats de l'etude randomisee de 60 cas. Bull Soc Ophtalmol Fr. 1982;94:149-154.
10. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1982;100:912-918.
11. Treatment of senile disciform macular degeneration: a single-blind randomised trial by argon laser photocoagulation. The Moorfields Macular Study Group. Br J Ophthalmol. 1982;66:745-753.
12. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthamol. 1990;108:825-831.
13. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol. 1993;115:786-791.
14. Möhle R, Green D, Moore MA, Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. PNAS. 1997;94:663-668.
15. Ciulla TA, Criswell MH, Danis RP. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol. 2001;119:399-404.
16. Chandler DB, Rozakis G, de Juan E Jr. The effect of triamcinolone acetonide on a refi ned experimental model of proliferative vitreoretinopathy. Am J Ophthalmol. 1985;99:686-690.
17. Hida T, Chandler D, Arena JE. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol. 1986;101:190-195.
18. Ishibashi T, Miki K, Sorgente N, Patterson R. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol. 1985;103:708-711.
19. Challa JK, Gillies MC, Penfold PL, Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol. 1998;26:277-281.
20. Penfold PL, Gyory JF, Hunyor AB Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol. 1995;23:293-298.
21. Danis RP, Ciulla TA, Pratt LM. Intravitreal triamcinolone aceotonide in exudative age-related macular degeneration. Retina. 2000;20:244-250.
22. Jonas JB, Akkoyun I, Budde WM. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol. 2004;122:218-222.
23. Gillies MC, Simpson JM, Luo W. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003;121:667-673.
24. Jonas JB, Degenring RF, Kreissig I. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005;112:593-598.
25. Rhee DJ, Peck RE, Belmont J. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol. 2006;90: 999-1003.
26. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfi n: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999;117:1329-1345.
27. Kaiser PK; Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfi n therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an openlabel extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol. 2006;244:1132-1142.
28. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541-560.
29. Blinder KJ, Bradley S, Bressler NM, et al; Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfi n in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfi n therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003;136:407-418.
30. Azab M, Boyer DS, Bressler NM, et al; Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfi n therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol. 2005;123:448-457.
31. Kannan R, Zhang N, Sreekumar PG, et al. Stimulation of apical and basolateral VEGF-A and VEGF-C secretion by oxidative stress in polarized retinal pigment epithelial cells. Mol Vis. 2006;12:1649-1659.
32. Gragoudas ES, Adamis AP, Cunningham ET Jr. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351: 2805-2816.
33. Rich RM, Rosenfeld PJ, Puliafi to CA. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511.
34. Spaide RF, Laud K, Fine HF. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383-390.
35. Bashshur ZF, Bazarbachi A, Schakal A. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142:1-9.
36. Rosenfeld PJ, Brown DM, Heier JS. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med. 2006;355:1419-1431.
37. Brown DM, Kaiser PK, Michels M. Ranibizumab versus verteporfi n for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
38. Kaiser PK, Brown DM, Zhang K. Ranibizumab for predominantly classic neovascular age-related macular degeneration: Subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144:850-857.
39. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and effi cacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:623-632.
40. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355: 1409-1412.
41. Fung AE, Lalwani GA, Rosenfeld PJ. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.
42. Regillo CD, Brown DM, Abraham P. Randomized, double-masked, shamcontrolled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study Year 1. Am J Ophthalmol. 2008;145:239-248.
43. Heier JS; the ANCHOR Study Group. Ranibizumab: Two-year ANCHOR Study results. Oral presentation. Retina Subspecialty Day, Annual Meeting of American Academy of Ophthalmology, New Orleans, USA; 2007.
44. Paolo L. Lessons Learned from the FOCUS Trial. Oral presentation. Retina Subspecialty Day, Annual Meeting of American Academy of Ophthalmology, New Orleans, USA; 2007.
45. Chiang A, Chang LK, Yu F. Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis. Retina. 2008 Jul 14. [Epub ahead of print].
46. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007;27:113-140.
47. Callanan DG. Unpublished study. Oral presentation. Retina Subspecialty Day, Annual Meeting of American Academy of Ophthalmology, New Orleans, USA; 2007.
48. Schmidt-Erfurth U, Wolf S. Paper submitted to Archives of Ophthalmology. Oral presentation. Retina Subspecialty Day, Annual Meeting of American Academy of Ophthalmology, New Orleans, USA; 2007.